Based on a genetic approach, use of cannabis was associated with increased risk of schizophrenia (odds ratio (OR) of schizophrenia for users vs nonusers of cannabis: 1.37; 95% confidence interval (CI), 1.09 1.67; P-value=0.007). The corresponding estimate from observational analysis was 1.43 (95% CI, 1.19 1.67; P-value for heterogeneity =0.76). The genetic markers did not show evidence of pleiotropic effects and accounting for tobacco exposure did not alter the association (OR of schizophrenia for users vs nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09 1.83). This adds to the substantial evidence base that has previously identified cannabis use to associate with increased risk of schizophrenia, by suggesting that the relationship is causal. Such robust evidence may inform public health messages about cannabis use, especially regarding its potential mental health consequences.
The epidemiology of mood disorder, pain and cognitive function
Mental health problems place a large burden on the health service. As life expectancy increases, understanding cognitive decline is increasingly important. Identifying high risk groups enables us to detect problems early and target resources. Understanding the distribution of disease between groups can help elucidate the causes of disease and help identify new methods of prevention and treatment. To examine the frequency, distribution, determinants and outcomes of these conditions, in relation to: demographics, lifestyle, comorbidity and medication
UKB is representative of the general population in terms of age, sex and ethnicity but unrepresentative in terms of lifestyle. Therefore, it is not suitable to determine the overall prevalence of any condition but can, nonetheless, be used to compare the distribution of diseases between sub-groups and therefore determine associations between risk factors and disease frequency and outcome. This project builds on our ongoing study (774) which examines ethnic differences in cardiometabolic disease. We seek to extend the focus to examine other determinants of cardiometabolic disease as well as determinants of mood disorder, cognitive impairment and pain.
Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants.
Low birth weight and features of neuroticism and mood disorder in 83 545 participants of the UK Biobank cohort.
|Lead investigator:||Jill Pell|
|Lead institution:||University of Glasgow|
There are no matching Categories